Hemstreet’s transition follows a period of strategic transformation led by Opgenorth, who stabilized the company’s commercial operations and refined its focus on genomic integrity. During his tenure as interim leader, Opgenorth oversaw the development of a proprietary genomic intelligence platform and strengthened the company's market messaging. Opgenorth will remain on the Board of Directors to support the leadership transition.

Bringing over a decade of experience from roles at Medtronic, Covidien, and Terumo Blood and Cell Technologies, Hemstreet is tasked with scaling KROMATID’s market footprint. His immediate priorities include accelerating the adoption of the KROMASURE™ platform and deepening strategic partnerships with pharmaceutical and biotechnology innovators. The company aims to establish its genomic integrity assessment tools as a universal quality metric for advanced cellular therapies, leveraging its ability to detect structural variations in gene editing.